MA27660A1 - Derive heteroarylcarbamoylbenzene - Google Patents

Derive heteroarylcarbamoylbenzene

Info

Publication number
MA27660A1
MA27660A1 MA28448A MA28448A MA27660A1 MA 27660 A1 MA27660 A1 MA 27660A1 MA 28448 A MA28448 A MA 28448A MA 28448 A MA28448 A MA 28448A MA 27660 A1 MA27660 A1 MA 27660A1
Authority
MA
Morocco
Prior art keywords
mmol
acid
methyl ester
methanesulfonyl
phenoxy
Prior art date
Application number
MA28448A
Other languages
English (en)
Inventor
Eiki Jun-Ichi
Hashimoto Noriaki
Iino Tomoharu
Nakashima Hiroshi
Nishimura Teruyuki
Takahashi Keiji
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of MA27660A1 publication Critical patent/MA27660A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

1HNMR(CDC13)(delta): 1.24(d, 3H,J=6.2Hz), 2.54(s, 3H), 3.72 (m,2H), 4.52(m,1H), 6.97(m,2H), 7.16(m/2H), 7.33(m,1H), 7.59(m,1H), 8.52(m,1H), 12.0(br,1H) ESI-MS(m/e): 402[M+H]+ Exemple de production 89 Préparation de 5-(2-hydroxy-1-méthyl-éthoxy)-3-(4-méthane-sulfonylphénoxy)-N-(3-méthyl-[1,2,4]-thiadiazol-5-yl)-benzamide Après l'addition de 33,4 g (142 mmol) de 4-méthane-sulfonyl-bromobenzène, 2,67 g (11,9 mmol) d'acétate de palladium, 5,31 g (17,8 mmol) de 2-(di-tert-butylphosphino)biphényle et 50,3 g (237 mmol) de phosphate de potassium à une solution de 25,0 g (119 mmol) d'ester méthylique de l'acide 5-hydroxy-3-méthoxyméthoxybenzoïque dans du toluène (375 ml), le réacteur a été bouché et le mélange a été agité par la suite à 130o.C pendant 6 heures. De l'ester éthylique d'acide acétique a été ajouté au mélange réactionnel, qui a alors été filtré et concentré sous pression réduite. Le résidu obtenu a été purifié par chromatographie sur colonne sur gel de silice (hexane : ester éthylique d'acide acétique = 2:1) pour obtenir 31,0 g d'ester méthylique de l'acide 3-(4-méthanesulfonyl-phénoxy) -5-méthoxyméthoxy-benzoïque (rendement : 69%) comme un solide blanc. Après l'addition de 60 ml d'acide trifluoroacétique à une solution de 30,9 g (84,3 mmol) de l'ester méthylique de l'acide 3-(4-méthanesulfonyl-phénoxy)-5-méthoxyméthoxy-benzoïque obtenu dans du chlorure de méthylène (100 ml) avec refroidissement sur glace, le mélange réactionnel a été agité à la température ambiante pendant 4 heures. Le mélange réactionnel a été concentré sous pression réduite, et le résidu obtenu a été purifié par chromatographie sur colonne sur gel de silice (hexane: ester éthylique d'acide acétique = 1:1) pour obtenir 15,2 g d'ester méthylique de l'acide 5-hydroxy- 3-(4-méthanesulfonyl-phénoxy)benzoïque (rendement: 56%) comme un solide blanc. Puis après l'addition de 11,8 g (62,1 mmol) de (2R)-1-(t-butyldiméthylsiloxy)-2-hydroxypropane et 16,3 g (62,1 mmol) de triphénylphosphine à une solution de 10,0 g (31,0 mmol) de l'ester méthylique de l'acide 5-hydroxy-3-(4-méthanesulfonyl-phénoxy)benzoïque obtenu dans du tétrahydrofurane (200 ml), 33,8 ml (77,6 mmol) d'une solution d'azodicarboxylate de diéthyle dans 40% de toluène ont été ajoutés avec refroidissement sur glace, et le mélange a été agité à la température ambiante pendant 12 heures. Le mélange réactionnel a été XX Composés ayant des effets d'activation de la glucokinase et étant utiles dans les traitements du diabète, qui sont représentés par la formule (I) suivante : [dans laquelle X1 représente l'oxygène, etc., X2 représente l'oxygène, etc., R1 représente un groupement sur le Noyau A tel que l'alkylsulfonyle, etc., R2 représente un C3-7 alkyle cyclique facultativement substitué par un halogène, etc., R3 représente un substituant sur le Noyau B tel que l'alkyle inférieur, etc., la formule (II): représente un aryle de 6 à 10 éléments, et la formule (III): représente un hétéroaryle monocyclique ou bicyclique ayant facultativement sur le Noyau B un substituant représenté par R3 ci-dessus, dans lequel l'atome de carbone du Noyau B est lié à l'atome d'azote du groupement amide dans la formule (I) forme une liaison C=N avec l'atome d'azote du noyau], ainsi que leurs sels pharmaceutiquement acceptables.
MA28448A 2003-02-26 2005-08-22 Derive heteroarylcarbamoylbenzene MA27660A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003049466 2003-02-26
JP2003400882 2003-11-28
JP2004031298 2004-02-06

Publications (1)

Publication Number Publication Date
MA27660A1 true MA27660A1 (fr) 2005-12-01

Family

ID=32931126

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28448A MA27660A1 (fr) 2003-02-26 2005-08-22 Derive heteroarylcarbamoylbenzene

Country Status (16)

Country Link
US (2) US7432287B2 (fr)
EP (1) EP1600442B1 (fr)
JP (1) JP4432901B2 (fr)
KR (1) KR20050105488A (fr)
CN (1) CN101712657A (fr)
AU (1) AU2004215514B2 (fr)
BR (1) BRPI0407810A (fr)
CA (1) CA2516407C (fr)
EC (1) ECSP055987A (fr)
MA (1) MA27660A1 (fr)
MX (1) MXPA05009059A (fr)
NO (1) NO20054425L (fr)
NZ (1) NZ541824A (fr)
RU (1) RU2330030C2 (fr)
UA (1) UA81468C2 (fr)
WO (1) WO2004076420A1 (fr)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
MXPA05003559A (es) 2002-10-03 2005-06-03 Novartis Ag (tiazol-2-il)-amida o sulfonamida substituida como activadores de glicocinasa utiles en el tratamiento de diabetes de tipo 2.
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US7629362B2 (en) * 2003-02-13 2009-12-08 Banyu Pharmaceutical Co., Ltd. 2-pyridine carboxamide derivatives
GB0325402D0 (en) * 2003-10-31 2003-12-03 Astrazeneca Ab Compounds
GB0327761D0 (en) * 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
US7728025B2 (en) * 2003-12-29 2010-06-01 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted benzimidazole derivative
BRPI0507746A (pt) * 2004-02-18 2007-07-10 Astrazeneca Ab composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
CA2554686A1 (fr) * 2004-02-18 2005-09-01 Astrazeneca Ab Composes
AU2005229416B2 (en) 2004-04-02 2009-03-26 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
KR20070006816A (ko) 2004-04-02 2007-01-11 노파르티스 아게 티아졸로피리딘 유도체, 이를 함유하는 제약 조성물 및글루코키나제 매개형 증상의 치료 방법
TW200600086A (en) * 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
GB0423044D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423043D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Compounds
GB0423042D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Chemical process
WO2006040527A1 (fr) * 2004-10-16 2006-04-20 Astrazeneca Ab Procede de fabrication de composes de phenoxy benzamide
US7414060B2 (en) * 2005-03-04 2008-08-19 Hoffmann-La Roche Inc. Pyridine-2-carboxyamide derivatives
US20110059941A1 (en) * 2005-05-24 2011-03-10 Peter William Rodney Caulkett 2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
NZ564608A (en) 2005-07-09 2009-09-25 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
RU2415141C2 (ru) * 2005-07-09 2011-03-27 Астразенека Аб Производные гетероарилбензамида для применения в качестве активаторов glk в лечении диабета
GB0514173D0 (en) * 2005-07-09 2005-08-17 Astrazeneca Ab Chemical compounds
US20110053910A1 (en) * 2005-07-09 2011-03-03 Mckerrecher Darren 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
US20100160286A1 (en) * 2005-08-09 2010-06-24 Astrazeneca Uk Limited Ab Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
US9202182B2 (en) * 2005-08-11 2015-12-01 International Business Machines Corporation Method and system for analyzing business architecture
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
JP2009508832A (ja) * 2005-09-16 2009-03-05 アストラゼネカ アクチボラグ グルコキナーゼ活性化剤としてのヘテロ二環式化合物
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
CA2623958C (fr) 2005-09-30 2013-05-28 Banyu Pharmaceutical Co., Ltd. Derive indole substitue en position 2 par un groupe heteroaryle
DE602006018496D1 (de) 2005-10-05 2011-01-05 Hoffmann La Roche Naphthyridin-derivate
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
US7910747B2 (en) * 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
MX2009000688A (es) 2006-07-24 2009-01-30 Hoffmann La Roche Pirazoles como activadores de glucocinasa.
AR063028A1 (es) 2006-10-06 2008-12-23 Banyu Pharma Co Ltd Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
TW200825063A (en) * 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
SA07280576B1 (ar) * 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
UA95815C2 (en) * 2006-10-26 2011-09-12 Астразенека Аб Benzoyl amino heterocyclyl compounds as glucokinase (glk) activators
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
BRPI0721143A2 (pt) 2006-12-21 2014-03-11 Astrazeneca Ab Forma cristalina do composto processo para a formação da mesma, uso de um composto, método para tratar doenças mediadas por ativador de glicocinase
WO2008083124A1 (fr) * 2006-12-28 2008-07-10 Rigel Pharmaceuticals, Inc. Composés d'hétérocycloalkyloxybenzamide n-substitués, et procédés d'utilisation
US8314247B2 (en) * 2007-01-10 2012-11-20 Mitsubishi Tanabe Pharma Corporation Hydrazone derivative
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
WO2008116107A2 (fr) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Activateurs de glucokinase
JP2010138073A (ja) * 2007-03-30 2010-06-24 Taisho Pharmaceutical Co Ltd ピコリン酸アミド化合物
CN101808995A (zh) * 2007-07-27 2010-08-18 百时美施贵宝公司 新颖的葡糖激酶激活剂及其使用方法
US8124632B2 (en) 2007-08-03 2012-02-28 Romark Laboratories, L.C. Alkylsulfonyl-substituted thiazolide compounds
MX2010001784A (es) 2007-08-13 2010-03-15 Metabasis Therapeutics Inc Activadores novedosos de la glucocinasa.
AR068540A1 (es) * 2007-09-28 2009-11-18 Merck & Co Inc Metodos de produccion de un derivado de pirazol-3-il-benzamida.
EA201000561A1 (ru) * 2007-10-09 2010-10-29 Мерк Патент Гмбх Производные пиридина, пригодные в качестве активаторов глюкокиназы
AU2008310115B2 (en) * 2007-10-09 2013-06-27 Merck Patent Gmbh N- ( pyrazole- 3 -yl) -benzamide derivatives as glucokinase activators
AU2008321959B2 (en) 2007-11-12 2014-02-13 Msd K.K. Heteroaryloxy quinazoline derivative
CA2707403A1 (fr) * 2007-12-25 2009-07-02 Banyu Pharmaceutical Co., Ltd. Derives de n-pyrazole-2-pyridinecarboxamide
PL2239253T3 (pl) * 2008-02-06 2013-11-29 Daiichi Sankyo Co Ltd Nowe pochodne fenylopirolowe
KR20100117137A (ko) * 2008-02-27 2010-11-02 메르크 파텐트 게엠베하 당뇨병 치료를 위한 카르복사마이드-헤테로아릴유도체
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
MX2011001333A (es) 2008-08-04 2011-03-15 Astrazeneca Ab Derivados de pirazolo [3, 4] pirimidin-4-ilo y sus usos para tratar la diabetes y obesidad.
JP2012500181A (ja) 2008-08-15 2012-01-05 Ｍｓｄ株式会社 アセチルピロリジニルインドール誘導体
EP2328892B1 (fr) * 2008-08-29 2013-01-16 Msd K.K. Dérivé d'oxotétrahydrofurann-2-yl-benzimidazole
PE20110303A1 (es) 2008-09-11 2011-05-21 Pfizer Derivados de heteroaril acetamidas como activadores de glucoquinasa
US8759539B2 (en) 2008-11-17 2014-06-24 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
UA104742C2 (uk) * 2008-12-19 2014-03-11 Эли Лилли Энд Компани Похідні арилциклопропілацетаміду, застосовні як активатори глюкокінази
WO2010082601A1 (fr) * 2009-01-16 2010-07-22 第一三共株式会社 Nouveau dérivé de pyrrole 2,5-disubstitué
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) * 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
ES2427279T3 (es) 2009-03-11 2013-10-29 Pfizer Inc. Derivados de benzofuranilo usados como inhibidores de glucocinasa
WO2010107610A1 (fr) * 2009-03-17 2010-09-23 Merck Sharp & Dohme Corp. Méthode de traitement du diabète et des états pathologiques correspondants par thérapie combinatoire et compositions contenant de tels composés
WO2010116177A1 (fr) 2009-04-09 2010-10-14 Astrazeneca Ab Dérivé de pyrazolo [4,5-e] pyrimidine et son utilisation pour traiter le diabète et l'obésité
WO2010116176A1 (fr) * 2009-04-09 2010-10-14 Astrazeneca Ab Dérivé de pyrazolo [4, 5-e] pyrimidine et son utilisation pour traiter le diabète et l'obésité
EP3078377A3 (fr) * 2009-05-12 2017-04-05 Romark Laboratories, L.C. Nitazoxanide et tizoxanide en tant qu'agents antiviraux
MX341877B (es) 2009-06-26 2016-09-06 Romark Laboratories L C * Compuestos y métodos para tratar influenza.
US20110021570A1 (en) * 2009-07-23 2011-01-27 Nancy-Ellen Haynes Pyridone glucokinase activators
US20120220567A1 (en) 2009-07-23 2012-08-30 Shipps Jr Gerald W Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (fr) 2009-07-23 2011-01-27 Schering Corporation Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
MY156175A (en) * 2009-07-31 2016-01-15 Cadila Healthcare Ltd Substituted benzamide derivatives as glucokinase (gk) activators
KR20120120204A (ko) * 2009-12-11 2012-11-01 아스텔라스세이야쿠 가부시키가이샤 벤즈아미드 화합물
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
WO2011095997A1 (fr) * 2010-02-08 2011-08-11 Advinus Therapeutics Private Limited Composés de benzamide à titre d'activateurs de glucokinase et leur application pharmaceutique
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
WO2011158149A1 (fr) * 2010-06-18 2011-12-22 Pfizer Inc. Dérivés de 2-(3,5-disubstitutedphenyl)pyrimidin-4(3h)-one
US9000154B2 (en) * 2010-10-19 2015-04-07 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
CN106278982B (zh) * 2011-06-02 2019-06-14 奇诺因私人有限公司 用于制备前列腺素酰胺的新的方法
CN104230892B (zh) * 2011-11-09 2016-12-07 福建海西新药创制有限公司 一组提高激酶活性的化合物及其应用
US20150057220A1 (en) 2012-04-16 2015-02-26 Kaneq Pharma Inc. Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors
CN118453592A (zh) 2012-05-17 2024-08-09 Vtv治疗有限责任公司 用于治疗糖尿病的葡萄糖激酶活化剂组合物
MA45714A (fr) * 2016-07-22 2019-05-29 Bristol Myers Squibb Co Activateurs de glucokinase et leurs procédés d'utilisation
WO2019023651A2 (fr) 2017-07-28 2019-01-31 Massachusetts Institute Of Technology Modulateurs du récepteur des androgènes à petite molécule
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
AU2019287437A1 (en) 2018-06-12 2020-09-10 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
WO2021167840A1 (fr) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Activateurs de glucokinase sulfone et sulfoxyde et leurs procédés d'utilisation
CN116194442A (zh) 2020-06-08 2023-05-30 维特卫治疗有限责任公司 {2-[3-环己基-3-(反式-4-丙氧基-环己基)-脲基]-噻唑-5-基硫烷基}-乙酸的盐或共晶体及其用途
CN113527146B (zh) * 2021-08-19 2023-04-18 广东药科大学 分子氧促进谐二氟烯烃羟化磺酰酯化反应制备β-羟基-谐二氟磺酰酯类化合物的方法
CN121712503A (zh) * 2023-06-16 2026-03-20 康特克斯生物科技美国公司 稠合二环杂环或杂芳基酰胺化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2125664C (fr) 1991-12-11 2000-01-25 Alfred Botha Methode d'obtention d'huile contenant de l'acide gamma-linolenique a partir d'une seule cellule
GB9725298D0 (en) * 1997-11-28 1998-01-28 Zeneca Ltd Insecticidal thiazole derivatives
US6268387B1 (en) * 1997-12-23 2001-07-31 Warner-Lambert Company Thiourea and benzamide compounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
WO2003080585A1 (fr) * 2002-03-26 2003-10-02 Banyu Pharmaceutical Co., Ltd. Derive aminobenzamide
GB0327761D0 (en) * 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
BRPI0507746A (pt) * 2004-02-18 2007-07-10 Astrazeneca Ab composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
CA2554686A1 (fr) * 2004-02-18 2005-09-01 Astrazeneca Ab Composes

Also Published As

Publication number Publication date
RU2005129729A (ru) 2006-03-20
EP1600442B1 (fr) 2018-01-17
US20090018056A1 (en) 2009-01-15
JPWO2004076420A1 (ja) 2006-06-01
CN101712657A (zh) 2010-05-26
US7754743B2 (en) 2010-07-13
CA2516407C (fr) 2013-07-09
NZ541824A (en) 2010-04-30
AU2004215514B2 (en) 2010-03-04
EP1600442A4 (fr) 2006-11-02
US20060167053A1 (en) 2006-07-27
WO2004076420A1 (fr) 2004-09-10
BRPI0407810A (pt) 2006-03-01
HK1091204A1 (zh) 2007-01-12
US7432287B2 (en) 2008-10-07
RU2330030C2 (ru) 2008-07-27
ECSP055987A (es) 2006-01-16
MXPA05009059A (es) 2005-10-19
NO20054425L (no) 2005-09-23
JP4432901B2 (ja) 2010-03-17
KR20050105488A (ko) 2005-11-04
UA81468C2 (en) 2008-01-10
EP1600442A1 (fr) 2005-11-30
AU2004215514A1 (en) 2004-09-10
CA2516407A1 (fr) 2004-09-10

Similar Documents

Publication Publication Date Title
JP2853227B2 (ja) ７置換‐ヘプト‐６‐エン酸、ヘプタン酸及び誘導体並びにそれらの中間体の製法
EP1840125B1 (fr) Intermédiaires pour la production de dioxane-2-alkylcarbamates
US5399577A (en) Isoxazole derivatives and salts thereof
WO2003084930A1 (fr) Derives de diphenylpyridine, leur preparation, les compositions pharmaceutiques en contenant
EP0610134A1 (fr) Dérivés de l'indole, de l'indazole et du benzisoxazole comme 5-Ht1-like agonistes
FR2671083A1 (fr) Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques.
JP4322685B2 (ja) イソキノリン誘導体
CA2554855A1 (fr) Derives de alkylpiperazine-et alkylhomopiperazine- carboxylates, leur preparation et leur application en tant qu'inhibiteurs de l'enzyme faah
FR2681325A1 (fr) Derives de l'aminomethyl-4 piperidine, leur preparation et leur application en therapeutique.
EP0424244A1 (fr) Dérivés d'aryl-3 oxazolidinone, leur procédé de préparation et leur application en thérapeutique
JP6429016B2 (ja) トリフルオロメタンスルホンアニリド化合物の製造方法
EP0511031B1 (fr) Dérivés d'aryl-3 oxazolidinone, leur procédé de préparation et leur application en thérapeutique
EP0211698A2 (fr) Dérivés de (dihydro-4,5 1H-imidazolyl-2)-2 dihydro-2,3 indole, leur préparation et leur application en thérapeutique
WO2002006228A1 (fr) Procede de production de 5-fluorooxyindole et procede de production d'un produit intermediaire de celui-ci
CH626341A5 (en) Process for the stereospecific synthesis of N-substituted pyrrolidines and their use
JPS61122264A (ja) トランス―４―置換―ｓ―プロリン類の製造法
FR2670780A1 (fr) Derives de 4-(acylamino)benzopyranes, leur preparation et leur application en therapeutique.
JPH11158115A (ja) 重水素化エステル類化合物
CH616659A5 (fr)
WO1998031671A1 (fr) Derives de pyridone, leur preparation et leur utilisation comme intermediaires de synthese
KR100426534B1 (ko) 아젤라스틴의 개선된 합성방법
EP1140841B1 (fr) Derives de 3-phenyl-2, 6-dioxopiperidin-3-yl propionamide et leur procede de preparation
FR2741071A1 (fr) Derives de 3-(benzofuran-5-yl)oxazolidin-2-one, leur preparation et leur application en therapeutique
FR2785903A1 (fr) Derives de 1-aminoethylquinoleine, leur preparation et leur application en therapeutique
JP3740783B2 (ja) ４−（２−アルケニル）−２，５−オキサゾリジンジオン類の製造法